It can temporarily darken stools, which patients should be warned about so they do not mistake it for GI bleeding [5]
GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have revolutionized weight loss and type 2 diabetes management
The Denmark-based company announced Wednesday it had received a Complete Response Letter for dasiglucagon, which it was proposing for the ultra-rare genetic disease congenital hyperinsulinism, due to the timing of a third-party manufacturing facility reinspection. In an initial visit, the FDA had flagged deficiencies in a third-party contract manufacturer, which the company claims had been resolved by the time of a reinspection in August/September 2024
This deficiency precludes the formulation of definitive, evidence-based recommendations for their therapeutic use at this time
(PubMed) Iyer R, Gupta A, Khan A, Hiremath S, Lokhandwala Y